The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.

A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.

However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.